Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Don't hold your breath

<< Previous

Bullboard Posts

Next >>

Post by IamFlooredon May 14, 2020 10:58am

157 Views

Post# 31027579

Don't hold your breath

I have skin in the game in this company. But, after their last press release whereupon they were willing to sink the common shareholders with the reverse split of 1-100, I have no confidence in this company. Combine that with the questionable details of that deal which just went away with no explanation...If it smells like a skunk, it most likely is...

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments